Filtered By:
Vaccination: Hepatitis Vaccine
Countries: Australia Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
CDC Endorses Novavax COVID-19 Shot for Adults
U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax—a more traditional kind of vaccine, health officials said Tuesday.
Regulators authorized the nation’s first so-called protein vaccine against COVID-19 last week, but the final hurdle was a recommendation from the Centers for Disease Control and Prevention.
“If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated,” Dr. Rochelle Walensky, CDC’s director, said in a s...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option.
Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial va...
Source: TIME: Health - June 8, 2022 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options.
Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news
Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Ambulance Science Podcast: Make Up Your Own Mind About the Vaccine
Get every episode of The Ambulance Science Podcast by subscribing to Apple Podcasts or Google Podcasts.
Where I’m coming from (compared to most of my colleagues):
Master’s in Public Health with a concentration in Health Policy from Yale Medical School.FT Faculty at GWU School of Medicine & Southern Connecticut State University MPH Program, and long-time adjunct faculty at NYMC MPH program in Health Policy.Assistant Commissioner of Health at the NYC Department of Health & Mental Hygiene during the first SARS outbreak.Served as State EMS Director, Consultant to Public Health ...
Source: JEMS Special Topics - December 14, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Podcasts Ambulance Science Source Type: news
Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with two separate inj...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial
Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines.
Trial Registration: www.ClinicalTrials.gov, identifier: NCT02071095.
Introduction
Innate immune dysregulation during HIV infection hinders the formation of anti-HIV adaptive immunity (1–6) resulting in rampant viral dissemination and progression to AIDS. Adherence to combination anti-retroviral therapy (cART) regimens controls viremia, restores CD4+T cell counts and reverses immune dysfunction to ...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research
Drought in the Semiarid Region of Brazil: Exposure, Vulnerabilities and Health Impacts from the Perspectives of Local Actors
Conclusion
The results obtained from this research shows, in general, the fragility in the social and political infrastructure necessary to improve the living conditions of populations, particularly those that depend on family agriculture in drought prone areas. The conditions of social, economic and environmental vulnerabilities presented in the region can be amplified by the drought process, and can aggravate the impacts resulting drought events, thus disadvantaging the population of this region, as shown in the Fig. 1.
The general perception of the interviewees of the health sector shows an agreement with what is found...
Source: PLOS Currents Disasters - October 29, 2018 Category: International Medicine & Public Health Authors: Aderita Sena Source Type: research
Tropical Travel Trouble 010 Fever, Arthralgia and Rash
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog
aka Tropical Travel Trouble 010
Peer Reviewer: Dr Jennifer Ho, ID physician QLD, Australia
You are an ED doc working in Perth over schoolies week. An 18 yo man comes into ED complaining of fever, rash a “cracking headache” and body aches. He has just hopped off the plane from Bali where he spent the last 2 weeks partying, boozing and running amok. He got bitten by “loads” of mosquitoes because he forgot to take insect repellent.
On examination he looks miserable,...
Source: Life in the Fast Lane - July 16, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine arthralgia dengue fever rash Source Type: blogs
Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog
aka Tropical Travel Trouble 009
The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs
The 1000th Thread!
This is the 1000th presentation to my bioethics blog since starting on Google Blogspot.com in 2004.There has been many topics covered. Though comments by the visitors has always been encouraged and, since as a " discussion blog " , comments leading to discussions I have felt was the definitive function here. Virtually none of the thread topics have gone unread and most have had some commentary, some with mainly particularly strong and emphatic opinions http://bioethicsdiscussion.blogspot.com/2013/01/should-pathologists-be-physicians.html, some with extensive up to 12 years long continued discussion http://bioethicsdiscussi...
Source: Bioethics Discussion Blog - December 24, 2017 Category: Medical Ethics Source Type: blogs
